I finally have my energy and confidence back!" Linda K., Blue Ash, OH "After menopause, I struggled with weight gain, low energy, and constant mood swings
After subcutaneous administration, tirzepatide binds to both GIP and GLP-1 receptors on pancreatic beta cells, enhancing insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release when blood glucose levels are elevated
SGLT2 inhibitorrelated adverse effects, including genital mycotic infections, volume depletion, and rarely ketoacidosis, remain clinically relevant and should be considered when these agents are prescribed as part of combination therapy and importantly, the intrinsic risk of hypoglycemia with combined GLP-1 receptor agonist and SGLT2 inhibitor therapy is low because neither class directly stimulates insulin secretion in a glucose-independent manner and when hypoglycemia occurs, it is more commonly related to concomitant insulin or sulfonylurea use rather than the combination itself [41, 42, 44]
Two of three criteria are sufficient for diagnosis
Diagnosis rate impact by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval Inpatient admission by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval The Importance of Adherence Across both diabetes and weight loss cohorts, adherence to GLP-1 therapy at 80% or higher amplifies cost benefits
While animal studies have shown promising results, human clinical trials remain limited, which is precisely why recategorization and the research it enables are so important
